The field of smoking cessation has been abuzz since the FDA approved Chantix (varenicline) in 2006. Pfizer’s studies showed better efficacy for Chantix than bupropion (Wellbutrin/Zyban), and the mechanism of action is fascinating. But several controversial issues have arisen to muddy the waters.
Read More
The NIAAA (National Institute on Alcohol Abuse and Alcoholism) has recently posted a practical guide for professionals interested in improving their skills in evaluating and treating patients with alcohol problems. Here are some useful tips for treating alcoholism, adapted both from the NIAAA and other sources.
Read More
The current issue of the American Journal of Psychiatry carries a meta-analysis of different psychosocial interventions for the treatment of substance abuse (Dutra L et al., Am J Psychiatry 2008 165: 179-187). This review focuses specifically on techniques for treating abusers of cannabis, cocaine, and opiates. What works the best, and what techniques can you bring into your practice.
Read More
Psychostimulants are commonly added to antidepressants in order to augment their effects, but most of the clinical trials have been either open or small controlled trials. In what may be the largest trial done to date, these investigators (who received funding from Janssen-Ortho, the maker of Concerta) randomized 145 depressed patients...
Read More
The U.S. Food and Drug Administration (FDA) warned healthcare professionals that patients taking antiepileptic drugs (AEDs) have twice the risk of suicidal behavior or ideation compared with those taking placebo.
Read More
Dr. Willenbring, there are now several medications with evidence for treating alcohol problems. It gets confusing to know which ones to use in which situations.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
